• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Artificial cells with emphasis on cell encapsulation of genetically engineered cells.

作者信息

Chang T M

机构信息

Artificial Cells & Organs Research Centre, Faculty of Medicine, McGill University, Montreal, Canada.

出版信息

Artif Organs. 1998 Nov;22(11):958-65. doi: 10.1046/j.1525-1594.1998.06243.x.

DOI:10.1046/j.1525-1594.1998.06243.x
PMID:9821530
Abstract

Artificial cells are prepared in the laboratory for medical and biotechnological applications. Encapsulated cells are being studied for the treatment of diabetes, liver failure, and other conditions. More recently, there have been extensive studies into the use of encapsulated genetically engineered cells for gene therapy. We recently found that daily orally administered artificial cells, each containing a genetically engineered microorganism, can lower the elevated urea level in uremic rats to normal levels. This may solve the final obstacle of the lack of an effective oral urea removal system for the simple and inexpensive oral treatment of uremia. This is important because 85% of the world's uremic population cannot afford standard dialysis. Other areas of artificial cell application include use in hemoperfusion. Red blood cell substitutes based on modified hemoglobin are already in Phase 3 clinical trials in patients. Artificial cells containing enzymes are being developed for clinical trial in hereditary enzyme deficiency disease and other diseases. They are also being investigated for drug delivery and for use in other applications in biotechnology, chemical engineering, and medicine.

摘要

相似文献

1
Artificial cells with emphasis on cell encapsulation of genetically engineered cells.
Artif Organs. 1998 Nov;22(11):958-65. doi: 10.1046/j.1525-1594.1998.06243.x.
2
Artificial cell biotechnology for medical applications.
Blood Purif. 2000;18(2):91-6. doi: 10.1159/000014430.
3
Artificial cells for cell and organ replacements.
Artif Organs. 2004 Mar;28(3):265-70. doi: 10.1111/j.1525-1594.2004.47343.x.
4
Microencapsulated genetically engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats.口服微囊化基因工程化的活大肠杆菌DH5细胞可维持尿毒症大鼠的正常血浆尿素水平。
Nat Med. 1996 Aug;2(8):883-7. doi: 10.1038/nm0896-883.
5
Artificial cells with emphasis on bioencapsulation in biotechnology.重点在于生物技术中生物包封的人工细胞。
Biotechnol Annu Rev. 1995;1:267-95. doi: 10.1016/s1387-2656(08)70054-1.
6
Artificial cells: 35 years.人工细胞:35年。
Artif Organs. 1992 Feb;16(1):8-12. doi: 10.1111/j.1525-1594.1992.tb00263.x.
7
Artificial cells for replacement of metabolic organ functions.
Artif Cells Blood Substit Immobil Biotechnol. 2003 May;31(2):151-61. doi: 10.1081/bio-120020173.
8
Present status of modified hemoglobin as blood substitutes and oral therapy for end stage renal failure using artificial cells containing genetically engineered cells.改良血红蛋白作为血液替代品的现状以及使用含有基因工程细胞的人工细胞对终末期肾衰竭进行口服治疗的现状。
Ann N Y Acad Sci. 2001 Nov;944:362-72. doi: 10.1111/j.1749-6632.2001.tb03848.x.
9
Artificial cells, encapsulation, and immobilization.
Ann N Y Acad Sci. 1999 Jun 18;875:71-83. doi: 10.1111/j.1749-6632.1999.tb08495.x.
10
Microencapsulated genetically engineered E. coli DH5 cells for plasma urea and ammonia removal based on: 1. Column bioreactor and 2. Oral administration in uremic rats.基于以下两点的用于去除血浆尿素和氨的微囊化基因工程大肠杆菌DH5细胞:1. 柱式生物反应器;2. 对尿毒症大鼠进行口服给药。
Artif Cells Blood Substit Immobil Biotechnol. 1996 May;24(3):201-18. doi: 10.3109/10731199609117436.

引用本文的文献

1
Droplet-based microfluidics for artificial cell generation: a brief review.用于人工细胞生成的基于液滴的微流控技术:简要综述
Interface Focus. 2016 Aug 6;6(4):20160011. doi: 10.1098/rsfs.2016.0011.
2
Protein-based blood substitutes: recent attempts at controlling pro-oxidant reactivity with and beyond hemoglobin.基于蛋白质的血替代品:近期尝试控制促氧化剂反应性的血红蛋白及超越血红蛋白的尝试。
Pharmaceuticals (Basel). 2013 Jul 4;6(7):867-80. doi: 10.3390/ph6070867.
3
Blood substitutes.血液替代品
Crit Care. 1999;3(5):R91-2. doi: 10.1186/cc363. Epub 1999 Sep 24.